Semaglutide is a GLP-1 receptor agonist, which works by mimicking hormones that control appetite and blood sugar, helping reduce food intake and promote weight loss when combined with a healthy lifestyle
DiFeliceantonio wouldnt recommend GLP-1 drugs as future frontline treatments for someone with alcohol use disorder who is underweight
Immune Modulation: The peptide's effects on inflammatory pathways suggest caution for: Active autoimmune conditions Immunocompromised individuals Those taking immunomodulatory medications Populations Requiring Extra Caution Avoid or Use Extreme Caution: Active cancer or history of cancer Pregnancy or breastfeeding Children and adolescents Severe cardiovascular disease Active infections Immediately pre or post-surgery (without medical guidance) Drug Interactions Theoretical Interactions Given BPC-157's mechanisms, theoretical interactions exist with: Medications Affecting NO System: Nitrates (nitroglycerin, isosorbide) PDE5 inhibitors (sildenafil, tadalafil) Some blood pressure medications Reasoning: Combined NO system effects Anticoagulants and Antiplatelets: Warfarin Aspirin Clopidogrel Direct oral anticoagulants Reasoning: Angiogenic effects may affect bleeding Growth Hormone and Related: HGH IGF-1 Other growth-promoting compounds Reasoning: Additive growth factor effects Immunomodulators: Corticosteroids TNF-alpha inhibitors Other immunosuppressants Reasoning: Overlapping immune effects NSAIDs A Special Case Interestingly, while drug interactions are generally concerning, research suggests BPC-157 may protect against NSAID damage
The laboratory-research handling reference for the compound is our retatrutide 10 mg vial research dosage and reconstitution reference, again a research-context description rather than a use recommendation
However, users should understand the emotional and clinical implications and always consult with a healthcare provider to interpret results and determine appropriate next steps
mineralocorticoid receptor antagonists (MRAs)
